In-Vivo Lentiviral CAR-T Lot Release

Developing in-vivo lentiviral CAR-T therapies introduces significant analytical hurdles because the vector is administered directly to the patient. Ensuring clinical success requires comprehensive characterization across both Drug Substance and Drug Product stages to guarantee safety, purity, potency, and structural integrity. Traditional, off-the-shelf assays often fall short when assessing critical quality attributes like viral replication competence and infectious titers, which dictate accurate dosing and patient safety.

Advanced, GMP-compliant testing panels offer the necessary scientific rigor to validate genome identity, confirm transgene expression, and measure exact vector concentrations. Furthermore, customizing potency assays with biologically relevant or receptor-expressing target cells allows developers to effectively evaluate real-world functional activity, cellular targeting, and downstream signaling. Access the complete lot release portfolio to learn how validated analytical solutions can streamline your regulatory path and advance your therapeutic programs with confidence.